Home / Letter From The Editor / April 12, 2018

April 12, 2018

Apr 12, 2018
 

As I was reviewing this months SGLT-2 Therapy edition I was reminded of how much this class of drugs has opened up dialogues on patient care in multiple disease states. With the older diabetes medications we talked A1c, Fasting, or Postprandial; all related to diabetes and there was not much else. Now with the wider acceptance and increased research on the SGLT-2’s we find ourselves talking about Cardiovascular Benefits, Weight Loss, Decreased Mortality as well as improved glucose levels.

This month one of the most knowledgeable thought leaders in the diabetes world, Yehuda Handelsman, shares his ideas for prescribing SGLT-2 Inhibitors.

 

Dave Joffe

Editor-in-chief